Luke Carter-Brzezinski
Research Subjects
Luke Carter-Brzezinski has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Abbas Zaidi
1 shared publicationBeauta Rath
1 shared publicationBenjamin Watkins
1 shared publicationBona Nou
1 shared publicationCarlotta Clemente
1 shared publicationChantha Hou
1 shared publication
Latest Publications
- Open Access
- 4 September 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
Insights into a global collaboration in hematology from a partnership in Cambodia
- 4 September 2026
- Published by Elsevier in Blood Global Hematology
- Vol. 2 (4)
Open AccessInsights into a global collaboration in hematology from a partnership in Cambodia
- 1 May 2021
- Published by Elsevier in Blood Reviews
- Vol. 47, 100780
Management of venous thromboembolism in athletes
- 1 May 2021
- Published by Elsevier in Blood Reviews
- Vol. 47, 100780
Management of venous thromboembolism in athletes
- Open Access
- 1 January 2021
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 8 (1) , 136-140
Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report
With the increased life expectancies of people with severe haemophilia A, diagnoses of disorders associated with increased age are likely to become more common. Multiple myeloma is a commonly diagnosed plasma cell dyscrasia, with incidence strongly related to age. Both the disease itself and specific myeloma therapies are associated with a significant increase in rates of venous thromboembolism (VTE). Management of VTE prophylaxis can be challenging, especially in patients with a bleeding disorder. In this case report, we describe the management of a patient with concurrent diagnosis of multiple myeloma and severe haemophilia A, undergoing first line myeloma chemotherapy. The patient was successfully managed on standard of care myeloma treatment, with use of emicizumab and venous thromboprophylaxis. This case demonstrates the successful management of a haematological malignancy and a bleeding disorder using integrated and multidisciplinary patient-focused care.
- 1 January 2021
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 8 (1) , 136-140
Open AccessManagement of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report
With the increased life expectancies of people with severe haemophilia A, diagnoses of disorders associated with increased age are likely to become more common. Multiple myeloma is a commonly diagnosed plasma cell dyscrasia, with incidence strongly related to age. Both the disease itself and specific myeloma therapies are associated with a significant increase in rates of venous thromboembolism (VTE). Management of VTE prophylaxis can be challenging, especially in patients with a bleeding disorder. In this case report, we describe the management of a patient with concurrent diagnosis of multiple myeloma and severe haemophilia A, undergoing first line myeloma chemotherapy. The patient was successfully managed on standard of care myeloma treatment, with use of emicizumab and venous thromboprophylaxis. This case demonstrates the successful management of a haematological malignancy and a bleeding disorder using integrated and multidisciplinary patient-focused care.